Q-omics provides the consensus-scored NBEA profile across patient tissues and cancer cell-line models. NBEA expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NBEA is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, NBEA protein abundance shows 25,602 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where NBEA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NBEA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NBEA survival associations across molecular data types. NBEA RNA expression shows survival associations in the most cancer types (27), followed by mutation status (10) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NBEA RNA expression–survival associations across cancer types. High NBEA expression shows unfavorable associations in UVM, COAD, UCEC and BLCA, but favorable associations in KIRC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NBEA RNA expression.
This table summarizes NBEA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for NBEA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NBEA shows lower tumor expression in COAD, BLCA, THCA, LUSC, UCEC and KICH. The COAD box plot shows higher NBEA RNA expression in normal versus tumor tissue (log2 FC = −1.190, t-test p < 0.001).
This table shows molecular features associated with NBEA in patient tissues and cancer cell lines. In patient samples, NBEA shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NBEA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
